| abstract |
The present application describes novel isoxazoline of formula I or II: n n n or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R 1 , R 2 , R 3 , R 4 , Z, U, X, Y, Z a , and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof. |